Related references
Note: Only part of the references are listed.Cutaneous Squamous Cell Carcinoma and Inflammation of Actinic Keratoses Associated with Sorafenib
Zita Dubauskas et al.
CLINICAL GENITOURINARY CANCER (2009)
Dermatologic symptoms associated with the multikinase inhibitor sorafenib
Caroline Robert et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib
David S. Hong et al.
ARCHIVES OF DERMATOLOGY (2008)
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor
Julien Autier et al.
ARCHIVES OF DERMATOLOGY (2008)
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
Madeleine M. Hipp et al.
BLOOD (2008)
Diagnosis and follow-up of keratoacanthoma-like lesions: Clinical-histologic study of 43 cases
Renata Ferreira Magalhaes et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2008)
Keratoacanthomas associated with sorafenib therapy
Heidi H. Kong et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor
M. E. Lacouture et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2006)
Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization
Ole Petter F. Clausen et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on Keratinocytes in human epidermis
Xiao-Yong Man et al.
MOLECULAR MEDICINE (2006)
Cutaneous side-effects of kinase inhibitors and blocking antibodies
C Robert et al.
LANCET ONCOLOGY (2005)
Cyclic AMP differentially regulates cell proliferation of normal human keratinocytes through ERK activation depending on the expression pattern of B-Raf
H Takahashi et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2004)
Share Paper
